Eltrombopag/eltrombopag efficacy and side effects

Eltrombopag is a thrombopoietin receptor agonist commonly used to treat chronic immune thrombocytopenia (ITP), certain types of aplastic anemia, and hepatitis C-related thrombocytopenia. It increases platelet production by stimulating megakaryocytes in the bone marrow, thereby helping patients maintain safe levels and reducing the risk of bleeding. It is an important treatment option currently recommended by multiple guidelines.

In practical applications, eltrombopag has shown a stable and long-lasting plate-raising effect, does not rely on blood transfusion, and does not directly suppress the immune system, providing an alternative for many patients who cannot tolerate steroid drugs or traditional immunosuppressants. The platelet count usually gradually increases within one to two weeks after taking the drug, which is especially suitable for chronic patients who are troubled by symptoms such as frequent bleeding, purpura, or uncontrolled menstruation.

However, as a long-term oral medication, eltrombopag may also be associated with certain side effects. More common side effects include headache, nausea, fatigue, and mild elevations in transaminases. In a small number of people, abnormal liver function or an increased risk of blood clots may also occur. Therefore, regular blood draws are required to monitor liver enzyme levels and platelet counts during medication in order to adjust the dosage or evaluate the safety of the medication. In addition, some patients may be intolerant to the dye components in the drug, especially those with hepatitis or hepatitis B virus carriers, and need to be used with caution.

The effects of Eltrombopag vary from person to person, so treatment needs to be adjusted individually and avoid taking it with iron-containing foods or supplements, as these substances will interfere with its absorption efficiency. It is recommended to take the medicine on an empty stomach or use it in conjunction with a low-calcium and low-iron diet to enhance its efficacy. Taken together, eltrombopag is an oral targeted drug that plays an important role in hematology treatment. It has brought positive improvements to many patients in terms of improving their quality of life and reducing their dependence on blood transfusions.

Reference materials:https://go.drugbank.com/drugs/DB06210